Lupin receives US FDA approval for Pitolisant tablets
Summary
- Indian pharmaceutical company Lupin Ltd. has secured approval from the US Food and Drug Administration (FDA) for its oral tablet formulation of Pitolisant.
- Pitolisant is a histamine H3-receptor antagonist indicated for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
- The approval covers a 10 mg and 20 mg tablet dosage, marking Lupin's entry into the US market for this novel therapeutic class.
- This clearance follows successful Phase III clinical trials demonstrating the drug’s efficacy and safety profile.
- The FDA nod is expected to boost Lupin's revenue streams and enhance India's reputation as a supplier of innovative medicines.
Key Facts
- · Company: Lupin Ltd.
- · Drug: Pitolisant tablets (10 mg and 20 mg)
- · Regulatory approval: US FDA
- · Therapeutic indication: Narcolepsy (excessive daytime sleepiness)
- · Mechanism: Histamine H3-receptor antagonist
- · Approval date: June 2026 (announcement date)
- · Market impact: First Indian firm with FDA‑approved Pitolisant product
- · Potential US market size: Estimated $200 million annually
Why it matters
The FDA approval underscores India's growing capabilities in developing and commercialising innovative drugs, contributes to the country's pharma export earnings, and expands treatment options for narcolepsy patients worldwide.
#Lupin#FDA#Pitolisant#Narcolepsy#Pharmaceuticals#DrugApproval